T-Cell Engagers at AACR 2026: Bridging Immune Cells to Solid Tumors

How next-generation bispecific molecules are solving the biggest challenges of cancer immunotherapy — and what trials are recruiting now.

Published April 27, 2026 • 8 min read

TL;DR: T-cell engagers (TCEs) physically bridge your immune T cells to cancer cells, forcing them to attack. At AACR 2026: tebentafusp showed 5-year survival data doubling long-term survival in uveal melanoma, new "masked" TCEs activate only inside tumors (solving the toxicity problem), and a startling discovery — tumors that resist KRAS inhibitors actually become more vulnerable to TCE-based therapy. Multiple TCE trials are recruiting across melanoma, kidney cancer, sarcoma, and other solid tumors.

What Are T-Cell Engagers?

Your immune system's T cells are powerful cancer killers — but they often can't find or recognize tumor cells. T-cell engagers (TCEs) solve this by acting as a physical bridge: one end grabs a T cell (via CD3), and the other end grabs a protein on the cancer cell. This forces the T cell to attack, regardless of whether it would have recognized the cancer on its own.

TCEs have already transformed treatment for blood cancers — blinatumomab for leukemia, teclistamab for myeloma. The challenge has been making them work in solid tumors, where toxicity (attacking normal tissues that share the target protein) and T cell exhaustion have limited effectiveness. AACR 2026 showcased solutions to both problems.

Tebentafusp: 5-Year Survival Data

The biggest clinical milestone for TCEs in solid tumors comes from tebentafusp (Kimmtrak) in metastatic uveal melanoma — a cancer that barely responds to standard immunotherapy.

            Phase 3 results (378 patients):
            5-year survival: 16% vs 8% — doubles the chance of being alive at 5 years
Historical 5-year survival in metastatic uveal melanoma was <5%
27% of patients had further tumor shrinkage after initial progression (vs 4% on control)
71% of 5-year survivors had undetectable circulating tumor DNA at baseline

        

What makes tebentafusp unique: it's an ImmTAC (immune-mobilizing monoclonal T cell receptor against cancer) — instead of targeting a surface protein, it targets a peptide fragment (gp100) presented on HLA-A*02:01 molecules. This lets it reach targets that conventional antibodies can't see, accessing the vast intracellular proteome.

Tebentafusp requires HLA-A*02:01 positivity (about 40-50% of Caucasian patients). A simple blood test determines eligibility.

New TCE for Kidney Cancer: XmAb819

XmAb819 (Xencor) is the first TCE showing clinical activity in clear cell renal cell carcinoma, targeting ENPP3 (a protein highly expressed on kidney cancer cells).

25% response rate in 20 evaluable patients (all heavily pretreated)
70% disease control rate
Well tolerated — Phase 3 dose selection anticipated in 2026

This is significant because kidney cancer has had no TCE options until now. XmAb819 uses a "2+1" format (bivalent tumor arm) for stronger binding to cancer cells.

Solving the Toxicity Problem: Conditional TCEs

The biggest barrier to TCEs in solid tumors has been on-target, off-tumor toxicity — the TCE activates T cells against normal tissues that express the same target protein. AACR 2026 showcased multiple solutions:

Approach	How It Works	Example
Masked/steric	A "cap" blocks the CD3 arm until removed by tumor-specific proteases	XTX601 (CLDN18.2) — zero CRS in animal studies
pH-dependent	Only activates in the acidic tumor microenvironment	CT-202 (Nectin-4) — active in bladder, CRC, lung, breast
Logic-gated (AND-gate)	Requires BOTH target proteins to be present on the same cell before activating	MP0632 — only activates when both mesothelin AND EpCAM are co-expressed
mRNA-encoded	Patient's body produces the TCE gradually (no sudden bolus)	ABO2203 — 100% response rate, zero CRS

The logic-gated approach (MP0632) is particularly elegant: normal cells that express only one of the two targets are spared, while cancer cells that express both are attacked. This dramatically improves the safety window.

Built-In Co-stimulation: Overcoming T Cell Exhaustion

First-generation TCEs only engage CD3 on T cells — a single activation signal that leads to T cell exhaustion over time. Next-generation TCEs add co-stimulatory signals (CD28 or CD2) directly into the molecule:

HLX3902 (STEAP1 x CD3 x CD28) — for prostate cancer. Enhanced killing at low tumor-to-immune cell ratios; sustained activity on repeated stimulation
ZW209 (DLL3 x CD3 x CD28) — for small cell lung cancer. Superior to bispecific benchmarks
EVOLVE104 (ULBP2/5/6 x CD3 x CD2) — Phase 1 ongoing. CD2 co-stimulation for sustained T cell activation

The KRAS Resistance Paradox

            Startling discovery: Tumors that develop resistance to KRAS small-molecule inhibitors (like sotorasib) actually become more sensitive to TCR-based targeting. Why? KRAS amplification (a common resistance mechanism) increases the density of KRAS-derived peptides presented on HLA molecules — giving TCE-based therapies more targets to grab onto.
        

CLSP-5282 (Clasp Therapeutics) is a first-in-class TCE targeting KRAS G12V peptide-HLA complexes. This suggests TCE therapy could be the ideal next step after KRAS inhibitor failure — particularly relevant for pancreatic cancer (~30% KRAS G12V) and colorectal cancer.

PRAME: A Broad Solid Tumor Target

PRAME is a cancer-testis antigen expressed across many solid tumors but not in most normal tissues — making it an ideal TCE target.

Brenetafusp (IMC-F106C) — PRAME-directed ImmTAC now in Phase 3 for first-line melanoma (+ nivolumab). Also in Phase 1/2 for ovarian and lung cancer.
IMA203CD8 — PRAME-directed TCR-T (a related approach) achieved molecular remission in a 17-year-old with multi-organ metastatic kidney cancer who had exhausted all options.
Afami-cel (Tecelra) — FDA-approved TCR-T targeting MAGE-A4 for synovial sarcoma (39% ORR). Expanding to other MAGE-A4+ tumors.

What This Means for Patients Seeking Trials

Uveal melanoma patients: Tebentafusp 5-year data confirms durable benefit. If you're HLA-A*02:01+, this should be discussed with your oncologist. Combination trials are recruiting.
Kidney cancer patients: XmAb819 is the first TCE showing activity in RCC. Phase 3 dose selection in 2026 — early access may be possible.
After KRAS inhibitor failure: If your pancreatic or colorectal cancer progressed on sotorasib or another KRAS inhibitor, TCE trials targeting KRAS peptides may be an option.
Know your HLA type: Many ImmTAC/TCR-mimic TCEs require HLA-A*02:01. A blood test can determine this.
Sarcoma patients: Afami-cel is FDA-approved for synovial sarcoma. Other MAGE-A4+ tumors may qualify for expansion trials.
Prostate and SCLC: Next-gen TCEs with co-stimulation (HLX3902, ZW209) are entering clinical trials.

Find T-Cell Engager Trials for Your Cancer

Disease-Specific Trial Pages

Browse recruiting trials for cancers with active TCE development:

Uveal Melanoma Trials — tebentafusp combinations, PRAME ImmTAC
Melanoma Trials — brenetafusp (PRAME) Phase 3, bispecific combinations
Renal Cell Carcinoma Trials — XmAb819 (ENPP3), EVOLVE104
Pancreatic Cancer Trials — KRAS G12V TCR-T, KRAS vaccines
Colorectal Cancer Trials — KRAS-targeted TCEs, NKD1 TCR-T
Sarcoma Trials — afami-cel (MAGE-A4), PRAME TCR-T
SCLC Trials — DLL3-targeted TCEs (ZW209, tarlatamab)
Prostate Cancer Trials — STEAP1 TCEs (HLX3902)
Ovarian Cancer Trials — CDH6 TCEs, mesothelin TCEs
Browse All Disease Trials

This article summarizes publicly presented data from the AACR 2026 Annual Meeting (April 2026, Chicago). It is intended for educational purposes and does not constitute medical advice. Always discuss treatment options with your oncologist. See also: ADC Therapies at AACR 2026 and Immunotherapy & Cell Therapy at AACR 2026.